GlaxoSmithKline (GSK; NYSE: GSK) announced that risvutatug rezetecan (Ris-Rez), a B7-H3-targeted antibody-drug conjugate (ADC), received Orphan Drug Designation (ODD) from Japan’s Ministry of Health, Labour and Welfare for the treatment of small-cell lung cancer (SCLC). The designation, supported by durable responses observed in the Phase 1 ARTEMIS-001 trial in extensive-stage SCLC (ES-SCLC), advances GSK’s global development of the Hansoh Pharma-licensed ADC, with a Phase 3 pivotal trial already underway.
Regulatory Milestone
Item
Detail
Agency
Japan Ministry of Health, Labour and Welfare (MHLW)
Phase 1 ARTEMIS-001 – durable responses in ES-SCLC patients
Global Rights
Worldwide ex-China (licensed from Hansoh Pharma)
Product Profile & Mechanism
Attribute
Ris-Rez Specification
Target
B7-H3 (CD276) – immune checkpoint protein overexpressed in SCLC and other solid tumors
Format
Antibody-drug conjugate (ADC) – fully human anti-B7-H3 mAb + topoisomerase inhibitor payload
Mechanism
Targeted delivery of cytotoxic payload to B7-H3-expressing cancer cells
Development Origin
Licensed from Hansoh Pharma (China) – GSK acquired exclusive worldwide rights ex-Greater China
Clinical Stage
Phase 3 global trial ongoing (NCT07099898)
Clinical Development Status
Study
Phase
Population
Status
Key Finding
ARTEMIS-001
Phase 1
Extensive-stage SCLC (ES-SCLC)
Completed/enrolling
Durable responses supporting Japan ODD
NCT07099898
Phase 3
Relapsed ES-SCLC
Ongoing since August 2025
Global pivotal trial for registration
Strategic Context & Market Impact
Factor
Implication
SCLC Unmet Need
~15% of lung cancers; 5-year survival <7%; ES-SCLC median survival ~12 months with standard chemo-immunotherapy; desperate need for effective second-line+ therapies
B7-H3 Target Validation
Highly expressed in >65% of SCLC; less prone to resistance vs. DLL3 (tarlatamab target); dual targeting opportunity
GSK Oncology Strategy
ADC portfolio expansion following Blenrep (BCMA-ADC) withdrawal; Ris-Rez anchors lung cancer ADC franchise with potential for B7-H3 solid tumor expansion (prostate, esophageal)
Japan Market Access
ODD provides 10-year market exclusivity, tax incentives, priority review – critical for early launch in high-burden SCLC market
Competitive Landscape
Tarlatamab (Amgen, DLL3 BiTE) approved 2024; Ris-Rez positions as ADC alternative with potentially improved durability and CNS penetration
Commercial Potential: Peak global sales (ex-China) $1–2 billion assuming approval in relapsed ES-SCLC and label expansion to other B7-H3+ tumors; Japan represents $150–200 million annual opportunity
China Rights: Retained by Hansoh Pharma; potential for complementary global development and regulatory harmonization
Forward‑Looking Statements This brief contains forward‑looking statements regarding Phase 3 trial outcomes, regulatory approvals, and commercial potential for risvutatug rezetecan in SCLC. Actual results may differ due to ADC toxicities (interstitial lung disease, neutropenia), competitive dynamics with DLL3-targeted therapies, and reimbursement negotiations for orphan oncology indications.-Fineline Info & Tech
By Fineline Cube